BioCentury | Jun 5, 2020
Emerging Company Profile

Epsilogen: co-opting IgE antibodies against cancer

Epsilogen is taking a long overlooked isotype of human antibodies -- the IgE class -- and leveraging their high affinity for immune effector cells to seek out and destroy solid tumors. “What we are doing...
BioCentury | Apr 16, 2020
Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

TScan, Novartis partner to develop TCR therapies  TScan Therapeutics Inc. entered an agreement with Novartis AG (NYSE:NVS; SIX:NOVN) to discover and develop TCR-engineered T cell therapies. Novartis will pay a technology access fee and research...
BioCentury | Mar 14, 2020
Emerging Company Profile

Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

Indapta is sidestepping genome engineering for its universal NK cells, a strategy that not only reduces manufacturing costs but also broadens the number of cancer patients it could treat relative to genetically edited allogeneic NK...
BioCentury | Feb 6, 2020

Feb. 5 Financial Quick Takes: Aimmune gets $200M Nestlé investment; plus Vineti, MaaT, Kezar, Ziopharm, Ikarovec

$200M for Aimmune as it expands allergy pipeline  Nestlé Health Science made a $200 million equity investment in Aimmune Therapeutics Inc. (NASDAQ:AIMT), giving it a 19.9% stake in the allergy company based on its outstanding...
BC Innovations | Aug 23, 2019
Distillery Techniques

Fecal levels of bacterial genes, metabolite in neonates as childhood allergic disease biomarker

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Tissue markers; gene profiling Neonatal fecal abundance of three bacterial epoxide hydrolase genes as well as their lipid-derived metabolite 12,13-diHOME could predict childhood development of allergic diseases including asthma, eczema and...
BC Innovations | Jul 11, 2019
Distillery Therapeutics

Treating asthma, allergic diseases with mAbs against crystallized proteins

DISEASE CATEGORY: Inflammation INDICATION: Asthma argenx and VIB have developed antibodies against LGALS10 that could help treat asthma and other allergic airway diseases. Patients with severe asthma had crystals comprising LGALS10 in airway tissue and...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BC Innovations | May 8, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | Apr 15, 2019
Distillery Therapeutics

Inhibitors of allergen-specific IgE responses for peanut allergy

DISEASE CATEGORY: Inflammation INDICATION: Allergy Cell culture studies identified two covalent, heterobivalent inhibitors of IgE responses against Ara h2 and Ara h6 that could help treat peanut allergy. The covalent heterobivalent inhibitors consist of an...
BC Innovations | Jan 16, 2019
Distillery Therapeutics


INDICATION: Allergy Patient sample and mouse studies suggest colonization with Anaerostipes caccae could help treat allergy to cow's milk in infants. In fecal samples from infants with cow's milk allergy, A. caccae counts were higher...
Items per page:
1 - 10 of 402